Contribution of the cyclin-dependent kinase inhibitor p27(KIP1) to the confluence-dependent resistance of HT29 human colon carcinoma cells

International Journal of Cancer

Volumn 77, Issue 5, 1998, Pages 796-802

  Dimanche Boitrel, Marie Thérèse ^a   Micheau, Olivier ^a   Hammann, Arlette ^a   Haugg, Monika ^a   Eymin, Béatrice ^a   Chauffert, Bruno ^a   Solary, Eric ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CISPLATIN; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HISTONE H1; PROTAMINE KINASE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL AGGREGATION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL;

APOPTOSIS; CELL ADHESION; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; G2 PHASE; GENES, P53; HT29 CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MITOSIS; POINT MUTATION; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0031875095     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980831)77:5<796::AID-IJC20>3.0.CO;2-Z     Document Type: Article

References (23)

1. KiPl protein: prognostic implications in primary breast cancer. Nature (Med.), 3, 227-230 (1997).
2. CHU, G., Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. biol. Chem., 269, 787-790 (1994).
3. KiPl induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene, 14, 2283-2289 (1997).
4. DEMARCQ, C., BUNCH, R.T., CRESWELL, D. and EASTMAN, A., The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differentiation, 5, 983-993 (1994).
5. DIMANCHE-BOITREL, M.T., GENNE, P., DUCHAMP, O. and CHAUFFERT, B., Confluence dependent resistance (CDR) to doxorubicin and E-cadherin expression in murine mammary cells. Cancer Lett., 85, 171-176 (1994).
6. DIMANCHE-BOITREL, M. T., PELLETIER, H., GENNE, P., PETIT, J. M., LE GRIMELLEC, C., ARDIET, C., BASTIAN, G. AND CHAUFFERT, B., Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Inf. J. Cancer, 50, 677-682 (1992).
7. DUBREZ, L., GOLDWASSER, F., GENNE, P., POMMIER, Y. and SOLARY, E., The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia, 9, 1013-1024 (1995).
8. EASTMAN, A., Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2, 276-280 (1990).
9. EL-DEIRY, W.S. and 15 OTHERS, WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174 (1994).
10. EVANS, D.L., TILBY, M. and DIVE, C., Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res., 54, 1596-1603 (1994).
11. GARRIDO, C., OTTAVI, P., FROMENTIN, A., HAMMANN, A., ARRIGO, A.P., CHAUFFERT, B. and MEHLEN, P., HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res., 57, 2661-2667 (1997).
12. KATAYOSE, Y., KIM, M., RAKKAR, A.N.S., LI, Z., COWAN, K.H. and SETH, P., Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res., 57, 5441-5445 (1997).
13. LODA, M., CUKOR. B., TAM, S.W., LAVIN, P., FIORENTINO, M., DRAETTA, G.F., JESSUP, J.M. and PAGANO, M., Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature (Med.), 3, 231-234 (1997).
14. KiPl display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell, 85, 707-720 (1996).
15. OLIVE, P.L. and DURAND, D.E., Drugs and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev., 13, 121-138 (1994).
16. PELLETIER, H., MILLOT, J.M., CHAUFFERT, B., MANFAIT, M., GENNE, P. and MARTIN, F., Mechanism of resistance of confluent human and rat colon . cancer cells to anthracyclines: alteration of drug-passive diffusion. Cancer Res., 50, 6626-6631 (1990).
17. Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66 ( 1994).
18. SCHIANO, M.A., SEVIN, B.U., PERRAS, J., RAMOS, R., WOLLOCH, E.H. and AVERETTA. H.E., In vitro enhancement of cis-platinum antitumor activity by caffeine and pentoxifylline, in a human ovarian cell line. Gynecol. Oncol., 43, 37-45 (1991).
19. 1 cyclin-dependent kinases. Genes Develop., 9, 1149-1163 (1995).
20. SHIMIZU, T., O'CONNOR, P.M., KOHN, K.W. and POMMIER, Y., Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res., 55, 228-231 (1995).
21. KiPlon resistance of tumor cells to anticancer agents. Nature (Med.), 2, 1204-1210 (1996).
22. VIKHANSKAYA, F., D'INCALCI, M. and BROGGINI, M., Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int. J. Cancer, 61, 397-401 (1995).
23. WANG, J. and WALSH, K., Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science, 273, 359-361 (1996).